Imipenem/Cliastatin Fresenius Kabi

Imipenem, the active ingredient in Imipenem/Cliastatin Fresenius Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in hospitalized adults and children when other therapies are unsuitable.

GNH USA supplies Imipenem/Cliastatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/cilastatin is a broad‑spectrum carbapenem used for infections that involve the bacterial cell wall and require intravenous therapy. - Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication. - Complicated urinary tract infections: resolves infection and prevents recurrence. - Skin and soft tissue infections: eliminates pathogenic bacteria and promotes healing. - Febrile neutropenia: provides rapid bacterial coverage in immunocompromised patients. - Community‑acquired pneumonia: treats severe pulmonary infection caused by susceptible organisms. - Hospital‑acquired pneumonia: effective against resistant nosocomial pathogens.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis during treatment. - Diarrhea: may be self‑limiting or indicate colitis. - Headache: transient cranial discomfort. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient hepatic enzyme rise.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Anaphylaxis: acute hypersensitivity requiring immediate intervention. - Clostridioides difficile infection: severe colitis risk. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: worsening kidney function in susceptible individuals.

Imipenem/cilastatin requires careful assessment before use to minimise risks. - Renal function: adjust dose in patients with impaired clearance. - History of seizures: avoid or monitor closely due to neurotoxicity potential. - Hypersensitivity: discontinue if allergic reactions develop. - Concomitant valproic acid: monitor for reduced seizure control. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drug interactions can affect efficacy or safety and should be evaluated.

Major Interactions (Avoid): - Valproic acid: reduces serum levels of valproate, risking breakthrough seizures. - Other carbapenems: concurrent use may increase toxicity without added benefit. - High‑dose sodium bicarbonate: may alter renal excretion of imipenem.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance nephrotoxic potential. - Aminoglycosides: combined nephrotoxicity risk. - NSAIDs: may affect renal function. - Warfarin: monitor INR for possible anticoagulant effect changes. - Oral contraceptives: possible reduction in efficacy, advise backup method.